VCEL Q1 2021 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35M+29.6% YoY

Gross Profit

$23M66.5% margin

Operating Income

-$3M-9.6% margin

Net Income

-$3M-9.5% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-23.6%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$8M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$211M

Total Liabilities

$71M

Stockholders' Equity

$140M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$27M	+29.6%
Gross Profit	$23M	$17M	+37.2%
Operating Income	-$3M	-$5M	+34.9%
Net Income	-$3M	-$5M	+30.1%

Revenue Segments

MACI Implants and Kits, and Epicel

$34M100%